Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance

International Journal of Cancer. Journal International Du Cancer
Wenlin ShaoPeter Atadja

Abstract

Panobinostat (LBH589) is a highly potent deacetylase inhibitor that has demonstrated clinical efficacy in patients with advanced cutaneous T-cell lymphoma (CTCL). To gain a better understanding of the compound activity in this tumor type, we investigated the cellular and molecular effects of panobinostat using both in vitro and in vivo models of CTCL. All 4 tested CTCL cell lines exhibited very high sensitivity to panobinostat-induced growth inhibition. However, only 2 of 4 lines exhibited significant response to the cytotoxic activity of panobinostat. In a CTCL xenograft mouse tumor model, panobinostat treatment resulted in complete tumor regression. The difference in cell sensitivity to panobinostat-induced death enabled us to further investigate potential mechanisms responsible for tumor sensitivity or resistance. In CTCL cell lines that were insensitive to panobinostat-induced apoptosis, constitutively activated NF-kappaB and high levels of Bcl-2 were observed. Inhibition of Bcl-2 sensitized cells to the cytotoxic activity of panobinostat. Conversely, knockdown of Bax diminished the CTCL cell sensitivity. Interestingly, panobinostat could induce cytotoxicity in vorinostat-resistant CTCL cells by downregulating phosphorylate...Continue Reading

References

Aug 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S SiegelT M Kuzel
Oct 12, 2001·Annals of the New York Academy of Sciences·B M Kacinski, M Flick
Oct 12, 2001·Annals of the New York Academy of Sciences·S J MeechR C Duke
Mar 5, 2002·Nature Immunology·Michael Karin, Anning Lin
Apr 6, 2002·Bioorganic & Medicinal Chemistry Letters·James E ThompsonJulie A DeMartino
Jan 18, 2003·Blood·Nicholas MitsiadesKenneth C Anderson
Aug 12, 2003·Oncogene·Michael L GatzaSusan J Marriott
Jul 29, 2004·Current Pharmaceutical Design·Richard Piekarz, Susan Bates
Apr 21, 2005·The Journal of Clinical Investigation·Ellen J KimAlain H Rook
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
Nov 19, 2005·Journal of Cutaneous Pathology·Günter BurgSean Whittaker
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David Z QianRoberto Pili
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Aug 31, 2007·World Journal of Gastroenterology : WJG·Thilo BluethnerMarcus Wiedmann
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leigh EllisH Miles Prince

❮ Previous
Next ❯

Citations

Dec 7, 2010·Investigational New Drugs·Jasmine Zain, Owen A O'Connor
Dec 17, 2010·Investigational New Drugs·Michael DickinsonH Miles Prince
Sep 9, 2011·Molecular Pharmaceutics·Robert W RobeySusan E Bates
Nov 30, 2011·Immunology and Cell Biology·Omar Khan, Nicholas B La Thangue
Apr 30, 2013·Nucleic Acids Research·Marco LodriniHedwig E Deubzer
May 23, 2012·Breast Cancer Research : BCR·Chandra R TateBridgette M Collins-Burow
Dec 1, 2011·Epigenomics·Inge VerbruggeMichael Bots
Apr 30, 2011·Future Medicinal Chemistry·Daniela MasciocchiDaniela Barlocco
Mar 16, 2012·Future Medicinal Chemistry·Sophia RangwalaMadeleine Duvic
Jun 6, 2014·Cellular and Molecular Life Sciences : CMLS·Jing Zhang, Qing Zhong
Apr 11, 2012·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Ouaïssi MehdiOuaïssi Ali
Apr 29, 2014·Pharmacology & Therapeutics·Prithviraj BoseSteven Grant
Nov 27, 2015·American Journal of Hematology·Ryan A Wilcox
Apr 10, 2012·Seminars in Oncology·Benedetta BelloniReinhard Dummer
Jun 24, 2014·Molecular Oncology·Victoria L LuchenkoSusan E Bates
Oct 13, 2011·American Journal of Hematology·Ryan A Wilcox
Jul 22, 2014·American Journal of Hematology·Ryan A Wilcox
Sep 23, 2014·Journal of Molecular Graphics & Modelling·Lan-Lan ZangRun-Ling Wang
Oct 30, 2012·Molecular Oncology·Angela NebbiosoLucia Altucci
Jun 9, 2016·Endocrine-related Cancer·Xuguang ZhuSheue-Yann Cheng
Nov 3, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Lubna Wasim, Madhu Chopra
Nov 2, 2016·Expert Opinion on Investigational Drugs·Prithviraj Bose, Srdan Verstovsek
Dec 19, 2013·The Journal of Organic Chemistry·Yalla Kiran KumarMaddi Sridhar Reddy
Mar 22, 2018·Journal of Clinical Medicine·Sabine WächterPietro Di Fazio
Jun 21, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Angie L McGraw
Jul 18, 2019·American Journal of Hematology·Alexandra C HristovRyan A Wilcox
Sep 29, 2017·Endocrinology and Metabolism·Xuguang Zhu, Sheue Yann Cheng
Oct 20, 2018·Oncology Letters·Tian-Jie HanXin Wang
Dec 25, 2013·International Journal of Oncology·Nicoletta FortunatiGiuseppe Boccuzzi
Jun 13, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Chong PengYan Dong
Oct 24, 2020·British Journal of Haematology·Julia J ScarisbrickPablo L Ortiz-Romero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.